Abstract:Importance The effect of glucocorticoids on major kidney outcomes and adverse events in IgA nephropathy has been uncertain. Objective To evaluate the efficacy and adverse effects of methylprednisolone in patients with IgA nephropathy at high risk of kidney function decline. Design, Setting, and Participants An international, multicenter, double-blind, randomized clinical trial that enrolled 503 participants with IgA nephropathy, proteinuria greater than or equal to 1 g per day, and estimated glomerular filtration rate (eGFR) of 20 to 120 mL/min/1.73 m(2) after at least 3 months of optimized background care from 67 centers in Australia, Canada, China, India, and Malaysia between May 2012 and November 2019, with follow-up until June 2021. Interventions Participants were randomized in a 1:1 ratio to receive oral methylprednisolone (initially 0.6-0.8 mg/kg/d, maximum 48 mg/d, weaning by 8 mg/d/mo; n = 136) or placebo (n = 126). After 262 participants were randomized, an excess of serious infections was identified, leading to dose reduction (0.4 mg/kg/d, maximum 32 mg/d, weaning by 4 mg/d/mo) and addition of antibiotic prophylaxis for pneumocystis pneumonia for subsequent participants (121 in the oral methylprednisolone group and 120 in the placebo group). Main Outcomes And Measures The primary end point was a composite of 40% decline in eGFR, kidney failure (dialysis, transplant), or death due to kidney disease. There were 11 secondary outcomes, including kidney failure. Results Among 503 randomized patients (mean age, 38 years; 198 [39%] women; mean eGFR, 61.5 mL/min/1.73 m(2); mean proteinuria, 2.46 g/d), 493 (98%) completed the trial. Over a mean of 4.2 years of follow-up, the primary outcome occurred in 74 participants (28.8%) in the methylprednisolone group compared with 106 (43.1%) in the placebo group (hazard ratio [HR], 0.53 [95% CI, 0.39-0.72]; P < .001; absolute annual event rate difference, -4.8% per year [95% CI, -8.0% to -1.6%]). The effect on the primary outcome was seen across each dose compared with the relevant participants in the placebo group recruited to each regimen (P for heterogeneity = .11): full-dose HR, 0.58 (95% CI, 0.41-0.81); reduced-dose HR, 0.27 (95% CI, 0.11-0.65). Of the 11 prespecified secondary end points, 9 showed significant differences in favor of the intervention, including kidney failure (50 [19.5%] vs 67 [27.2%]; HR, 0.59 [95% CI, 0.40-0.87]; P = .008; annual event rate difference, -2.9% per year [95% CI, -5.4% to -0.3%]). Serious adverse events were more frequent with methylprednisolone vs placebo (28 [10.9%] vs 7 [2.8%] patients with serious adverse events), primarily with full-dose therapy compared with its matching placebo (22 [16.2%] vs 4 [3.2%]). Conclusions and Relevance Among patients with IgA nephropathy at high risk of progression, treatment with oral methylprednisolone for 6 to 9 months, compared with placebo, significantly reduced the risk of the composite outcome of kidney function decline, kidney failure, or death due to kidney disease. However, the incidence of serious adverse events was increased with oral methylprednisolone, mainly with high-dose therapy.

The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) Study: Trial Design and Baseline Characteristics.

WCN24-1001 EFFECT OF CORTICOSTEROIDS ON KIDNEY AND SAFETY OUTCOMES IN IGA NEPHROPATHY ACROSS DIFFERENT LEVELS OF PROTEINURIA AND EGFR: A POST HOC ANALYSIS OF THE TESTING STUDY

Effect of Oral Methylprednisolone on Clinical Outcomes in Patients with Iga Nephropathy the Testing Randomized Clinical Trial

Corticosteroids in the treatment of IgA nephropathy: lessons from the TESTING trial

Efficacy and Safety of Glucocorticoids Therapy for IgA Nephropathy: a Meta-Analysis of Randomized Controlled Trials.

The Efficacy and Safety of Reduced-Dose Oral Methylprednisolone in High-Risk Immunoglobulin A Nephropathy

WCN23-0069 EFFICACY AND SAFETY OF REDUCED-DOSE ORAL METHYLPREDNISOLONE IN IGA NEPHROPATHY: THE TESTING TRIAL

Corticosteroid Therapy in IgA Nephropathy with Minimal Change-Like Lesions: a Single-Centre Cohort Study.

The safety of corticosteroid therapy in IGA nephropathy: analysis of a real-life Italian cohort

Corticosteroid therapy in IgA nephropathy with minimal proteinuria and high renal pathological score: A single‑center cohort study

Corticosteroid in IgA nephropathy with moderate proteinuria: A retrospective cohort study

Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients with IgA Nephropathy

Comparison Of Glucocorticoids Alone And Combined With Cyclosporine A In Patients With Iga Nephropathy: A Prospective Randomized Controlled Trial

Acei/Arb Therapy for Iga Nephropathy: A Meta Analysis of Randomised Controlled Trials

The Selective Endothelin Receptor Antagonist SC0062 in IgA Nephropathy

Correlation of Urinary Soluble CD163 Levels with Disease Activity and Treatment Response in IgA Nephropathy

Correlation of Urinary Soluble CD163 LevelsWith Disease Activity and TreatmentResponse in IgA Nephropathy

Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial.

Mycophenolate Mofetil Combined With Prednisone Versus Full-Dose Prednisone in IgA Nephropathy With Active Proliferative Lesions: A Randomized Controlled Trial

Shorter versus longer corticosteroid duration and recurrent immune checkpoint inhibitor-associated AKI

A Multicenter Application and Evaluation of the Oxford Classification of IgA Nephropathy in Adult Chinese Patients